BACKGROUND: The development of brain metastases (BMs) was associated with poor prognosis in melanoma patients. Patients with BMs have a median survival of <6 months. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %. Our aim was to identify factors predicting development of BMs and survival. PATIENTS AND METHODS: We performed a retrospective analysis of 470 melanoma patients between 2000 and 2012. The logistic regression analyses were used to identify the clinicopathological features of primary melanoma that are predictive of BMs development and survival after a diagnosis of brain metastases. RESULTS: There were 52 patients (11.1 %) who developed melanoma BMs during the study period. The analysis of post-BMs with Kaplan-Meier curves has resulted in a median survival rate of 4.1 months (range 2.9-5.1 months). On logistic regression analysis site of the primary tumor on the head and neck (p = 0.002), primary tumor thickness (Breslow >4 mm) (p = 0.008), ulceration (p = 0.007), and pathologically N2 and N3 diseases (p = 0.001) were found to be significantly associated with the development of BMs. In univariate analysis, tumor thickness and performance status had a significant influence on post-BMs survival. In multivariate analysis, these clinicopathologic factors were not remained as significant predictive factors. CONCLUSIONS: Our results revealed the importance of primary tumor characteristics associated with the development of BMs. Ulceration, primary tumor thickness, anatomic site, and pathologic ≥N2 disease were found to be significant predictors of BMs development.
BACKGROUND: The development of brain metastases (BMs) was associated with poor prognosis in melanomapatients. Patients with BMs have a median survival of <6 months. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %. Our aim was to identify factors predicting development of BMs and survival. PATIENTS AND METHODS: We performed a retrospective analysis of 470 melanomapatients between 2000 and 2012. The logistic regression analyses were used to identify the clinicopathological features of primary melanoma that are predictive of BMs development and survival after a diagnosis of brain metastases. RESULTS: There were 52 patients (11.1 %) who developed melanoma BMs during the study period. The analysis of post-BMs with Kaplan-Meier curves has resulted in a median survival rate of 4.1 months (range 2.9-5.1 months). On logistic regression analysis site of the primary tumor on the head and neck (p = 0.002), primary tumor thickness (Breslow >4 mm) (p = 0.008), ulceration (p = 0.007), and pathologically N2 and N3 diseases (p = 0.001) were found to be significantly associated with the development of BMs. In univariate analysis, tumor thickness and performance status had a significant influence on post-BMs survival. In multivariate analysis, these clinicopathologic factors were not remained as significant predictive factors. CONCLUSIONS: Our results revealed the importance of primary tumor characteristics associated with the development of BMs. Ulceration, primary tumor thickness, anatomic site, and pathologic ≥N2 disease were found to be significant predictors of BMs development.
Authors: Jan Zakrzewski; Laurel N Geraghty; Amy E Rose; Paul J Christos; Madhu Mazumdar; David Polsky; Richard Shapiro; Russell Berman; Farbod Darvishian; Eva Hernando; Anna Pavlick; Iman Osman Journal: Cancer Date: 2010-11-08 Impact factor: 6.860
Authors: Alexander M M Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena Musat; Alain Spatz; Ulrich Keilholz Journal: Lancet Date: 2008-07-12 Impact factor: 79.321
Authors: K M Fife; M H Colman; G N Stevens; I C Firth; D Moon; K F Shannon; R Harman; K Petersen-Schaefer; A C Zacest; M Besser; G W Milton; W H McCarthy; J F Thompson Journal: J Clin Oncol Date: 2004-04-01 Impact factor: 44.544
Authors: Omar Eton; Sewa S Legha; Agop Y Bedikian; J Jack Lee; Antonio C Buzaid; Cynthia Hodges; Sigrid E Ring; Nicholas E Papadopoulos; Carl Plager; Mary Jo East; Feng Zhan; Robert S Benjamin Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: C Frenard; L Peuvrel; M Saint Jean; A Brocard; A C Knol; J M Nguyen; A Khammari; G Quereux; B Dreno Journal: J Neurooncol Date: 2015-10-28 Impact factor: 4.130
Authors: Laura J Gardner; Morgan Ward; Robert H I Andtbacka; Kenneth M Boucher; Glen M Bowen; Tawnya L Bowles; Adam L Cohen; Kenneth Grossmann; Ying J Hitchcock; Sheri L Holmen; John Hyngstrom; Hung Khong; Martin McMahon; Marcus M Monroe; Carolyn B Ross; Gita Suneja; David Wada; Douglas Grossman Journal: Melanoma Res Date: 2017-10 Impact factor: 3.599
Authors: Aryana M Razmara; Luke A Wittenburg; Sami Al-Nadaf; Ryan G Toedebusch; Frederick J Meyers; Christine M Toedebusch Journal: Front Oncol Date: 2022-05-27 Impact factor: 5.738
Authors: Wolfram E Samlowski; James Moon; Merle Witter; Michael B Atkins; John M Kirkwood; Megan Othus; Antoni Ribas; Vernon K Sondak; Lawrence E Flaherty Journal: Cancer Med Date: 2017-10-10 Impact factor: 4.452